eNewsroom for: Neuralgene

http://pressreleaseheadlines.com/wp-content/Cimy_User_Extra_Fields/Neuralgene/Screen Shot 2013-04-11 at 6.25.34 PM.png

Neuralgene Company Profile

Neuralgene is a biotechnology company with the focus of developing gene therapy for Neurodegenerative disorders. Neuralgene’s main development is PRCN-829, an AAV based gene therapy for the treatment of ALS. This gene therapy targets several key underlying mechanisms of ALS. This therapy is designed to not only target gene delivery to the brain and spinal cord, but also to genetically engineer stem cells. Neuralgene will be working in conjunction with Precision StemCell of Bogota, Colombia. Neuralgene’s gene therapy technology is based off of stem cell work performed by Jason Williams, MD. Dr. Williams determined that stem cells are producing substances that inhibit the process of ALS. The problem with stem cell therapy used alone, though it can be beneficial, it does not seem to have permanent lasting results. This has been shown with several different stem cell treatments in regards to ALS. PRCN-829 was developed to provide the benefits that occur with stem cell therapy, but to amplify and lengthen the effects. The effect of AAV gene therapy last for many years and may actually be lifelong.

News from Neuralgene:

Biotechnology Company Neuralgene Provides Hope to Children With Genetic Disorder ALD, Announces First Human Patient of New Genetic Therapy

GULF SHORES, Ala., April 29, 2014 /PRNewswire/ — If successful, Neuralgene's (http://www.neuralgene.com) PRCN-323 treatment could significantly change the prognosis for everyone with the rare genetic disorder known as adrenoleukodystrophy, or ALD. The biotech company has recently celebrated a series of early successes in the treatment of other neurological conditions like ALS (Lou Gehrig's disease). Founder and […]

Gene Therapy Developed for ALS Treatment: New Biotech Company Neuralgene Enters Evaluation Phase

Patent-pending PRCN-829 delivers multiple genes, including Factor H, neural growth factors and regulators of TDP-43 to treat neurodegenerative disease ALS BOGOTA, Colombia, April 12, 2013 /PRNewswire/ — Startup biotechnology company Neuralgene (http://neuralgene.com) has announced that it will begin animal studies in May to evaluate the efficacy of PRCN-829, its new gene therapy agent for the […]